Ensysce Biosciences Shares Surge Over 50% on Strategic Review News

Shares of Ensysce Biosciences (NASDAQ: ENSC) soared in pre-market trading after the company announced it has initiated a formal strategic review to explore its options, which could include a sale, partnership, or other transactions.

Strategic Review Ignites Rally

The stock jumped 52.6% to $0.4274 in pre-open trading, according to figures reported by Investing.com. The move marks a significant reversal for the micro-cap biotech firm, whose shares had recently traded near a 52-week low of $0.23. Ensysce Biosciences stated its board will consider a range of alternatives, such as partnerships, licensing agreements, or the sale of company assets.

Underlying Clinical and Funding Momentum

The decision to explore strategic options follows several positive developments that may enhance the company's value in a potential transaction. These recent catalysts include:

Ad

• A Notice of Award for $5.3 million from the National Institute on Drug Abuse (NIDA) to support the development of its MPAR overdose-protection technology.
• The initiation of the final stage of its PF614-MPAR-102 clinical study, which evaluates the same overdose-protection platform.

Ensysce is a clinical-stage company focused on developing safer pain relief medications with its proprietary Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistant (MPAR) platforms, which are designed to reduce the potential for opioid misuse and abuse.

Market Outlook

The combination of a potential corporate transaction, recent non-dilutive government funding, and clinical progress appears to have fueled significant investor optimism. While the stock remains well below its 52-week high of $2.75, the strategic review suggests that management believes a deal could unlock substantial value from its specialized opioid technology platforms.